Wondonin, a novel compound, inhibits hypoxia-induced angiogenesis through hypoxia-inducible factor 1 alpha

FEBS Letters

Volumn 581, Issue 25, 2007, Pages 4977-4982

  Jun, Hyoung Oh ^a   Kim, Younghwa ^b   Kwon, Yoo Wook ^c   Hong, Soon Sun ^a   Kim, Kyu Won ^a   Shin, Jongheon ^a   Kim, Tae Yoon ^b  

^a Seoul National University   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Angiogenesis; Anti angiogenic activity; HIF 1 ; VEGF; Wondonin

Indexed keywords

CD31 ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMIDAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN; WONDONIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL LINE; CONTROLLED STUDY; DOWN REGULATION; EPIDERMIS HYPERPLASIA; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOREACTIVITY; IN VITRO SELECTION; IN VIVO STUDY; KERATINOCYTE; MOUSE; NONHUMAN; POECILLASTRA WONDOENSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPONGE (PORIFERA);

ANGIOGENESIS INHIBITORS; ANIMALS; CELL HYPOXIA; CELL LINE; CHICK EMBRYO; DOWN-REGULATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMIDAZOLES; MALE; MICE; SULFURIC ACID ESTERS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MUS; POECILLASTRA;

EID: 35148883954     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2007.09.034     Document Type: Article

References (33)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285 (1971) 1182-1186
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1 (1995) 27-31
3. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
4. Risau W. Mechanisms of angiogenesis. Nature 386 (1997) 671-674
5. Leong T.T., Fearon U., and Veale D.J. Angiogenesis in psoriasis and psoriatic arthritis: clues to disease pathogenesis. Curr. Rheumatol. Rep. 7 (2005) 325-329
6. Bussolino F., Mantovani A., and Persico G. Molecular mechanisms of blood vessel formation. Trends Biochem. Sci. 22 (1997) 251-256
7. Isner J.M., and Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J. Clin. Invest. 103 (1999) 1231-1236
8. Kwon Y.W., et al. Insulin-like growth factor-II regulates the expression of vascular endothelial growth factor by the human keratinocyte cell line HaCaT. J. Invest. Dermatol. 123 (2004) 152-158
9. Pili R., and Donehower R.C. Is HIF-1 alpha a valid therapeutic target?. J. Natl. Cancer Inst. 95 (2003) 498-499
10. Hockel M., and Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 93 (2001) 266-276
11. Folkman J., and Klagsbrun M. Angiogenic factors. Science 235 (1987) 442-447
12. Maxwell P.H., et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA 94 (1997) 8104-8109
13. Keppler B.K., and Rupp W. Antitumor activity of imidazolium-bisimidazole-tetrachlororuthenate (III). A representative of a new class of inorganic antitumor agents. J. Cancer Res. Clin. Oncol. 111 (1986) 166-168
14. Shin J.H., Rho J.R., Seo Y.W., Lee H.S., Lee H.S., Cho K.W., Kwon H.J., and Sim C.J. Wondonins A and B, new bis(dihydroxystyryl)imidazoles from a two-sponge association. Tetrahedron Lett. 42 (2001) 1965-1968
15. Folkman J., Haudenschild C.C., and Zetter B.R. Long-term culture of capillary endothelial cells. Proc. Natl. Acad. Sci. USA 76 (1979) 5217-5221
16. Auerbach R., Kubai L., Knighton D., and Folkman J. A simple procedure for the long-term cultivation of chicken embryos. Dev. Biol. 41 (1974) 391-394
17. Kim J.K., Kim Y., Na K.M., Surh Y.J., and Kim T.Y. [6]-Gingerol prevents UVB-induced ROS production and COX-2 expression in vitro and in vivo. Free Radic. Res. 41 (2007) 603-614
18. Tang N., Wang L., Esko J., Giordano F.J., Huang Y., Gerber H.P., Ferrara N., and Johnson R.S. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 6 (2004) 485-495
19. Kondo K., Klco J., Nakamura E., Lechpammer M., and Kaelin Jr. W.G. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1 (2002) 237-246
20. Maranchie J.K., Vasselli J.R., Riss J., Bonifacino J.S., Linehan W.M., and Klausner R.D. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1 (2002) 247-255
21. Maxwell P.H., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
22. Slaga T.J. Multistage skin carcinogenesis: a useful model for the study of the chemoprevention of cancer. Acta Pharmacol. Toxicol. (Copenh) 55 Suppl. 2 (1984) 107-124
23. Lee W.Y., Lockniskar M.F., and Fischer S.M. Interleukin-1 alpha mediates phorbol ester-induced inflammation and epidermal hyperplasia. Faseb J. 8 (1994) 1081-1087
24. Zhou L., Dosanjh A., Chen H., and Karasek M. Divergent effects of extracellular oxygen on the growth, morphology, and function of human skin microvascular endothelial cells. J. Cell Physiol. 182 (2000) 134-140
25. Bokhari S.M., Zhou L., Karasek M.A., Paturi S.G., and Chaudhuri V. Regulation of skin microvasculature angiogenesis, cell migration, and permeability by a specific inhibitor of PKCalpha. J. Invest. Dermatol. 126 (2006) 460-467
26. Semenza G.L. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit. Rev. Biochem. Mol. Biol. 35 (2000) 71-103
27. Blagosklonny M.V. Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review). Int. J. Oncol. 19 (2001) 257-262
28. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3 (2003) 721-732
29. Lisztwan J., Imbert G., Wirbelauer C., Gstaiger M., and Krek W. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev. 13 (1999) 1822-1833
30. Desbaillets I., Diserens A.C., de Tribolet N., Hamou M.F., and Van Meir E.G. Regulation of interleukin-8 expression by reduced oxygen pressure in human glioblastoma. Oncogene 18 (1999) 1447-1456
31. Harmey J.H., Dimitriadis E., Kay E., Redmond H.P., and Bouchier-Hayes D. Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1. Ann. Surg. Oncol. 5 (1998) 271-278
32. Lal A., et al. Transcriptional response to hypoxia in human tumors. J. Natl. Cancer Inst. 93 (2001) 1337-1343
33. Shweiki D., Itin A., Soffer D., and Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359 (1992) 843-845